JP2006504795A5 - - Google Patents

Download PDF

Info

Publication number
JP2006504795A5
JP2006504795A5 JP2005500374A JP2005500374A JP2006504795A5 JP 2006504795 A5 JP2006504795 A5 JP 2006504795A5 JP 2005500374 A JP2005500374 A JP 2005500374A JP 2005500374 A JP2005500374 A JP 2005500374A JP 2006504795 A5 JP2006504795 A5 JP 2006504795A5
Authority
JP
Japan
Prior art keywords
dosage
period
composition
active ingredient
twice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2005500374A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006504795A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/031622 external-priority patent/WO2004030633A2/en
Publication of JP2006504795A publication Critical patent/JP2006504795A/ja
Publication of JP2006504795A5 publication Critical patent/JP2006504795A5/ja
Withdrawn legal-status Critical Current

Links

Images

JP2005500374A 2002-10-03 2003-10-03 神経学的障害を処置するための抗うつ剤の投薬量の段階的な漸増ならびに毎日の分割した投薬 Withdrawn JP2006504795A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41573902P 2002-10-03 2002-10-03
US43155002P 2002-12-06 2002-12-06
US44308103P 2003-01-28 2003-01-28
US44320303P 2003-01-28 2003-01-28
PCT/US2003/031622 WO2004030633A2 (en) 2002-10-03 2003-10-03 Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010173175A Division JP2010275314A (ja) 2002-10-03 2010-07-30 神経学的障害を処置するための抗うつ剤の投薬量の段階的な漸増ならびに毎日の分割した投薬

Publications (2)

Publication Number Publication Date
JP2006504795A JP2006504795A (ja) 2006-02-09
JP2006504795A5 true JP2006504795A5 (enExample) 2010-09-16

Family

ID=32074649

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2005500374A Withdrawn JP2006504795A (ja) 2002-10-03 2003-10-03 神経学的障害を処置するための抗うつ剤の投薬量の段階的な漸増ならびに毎日の分割した投薬
JP2010173175A Pending JP2010275314A (ja) 2002-10-03 2010-07-30 神経学的障害を処置するための抗うつ剤の投薬量の段階的な漸増ならびに毎日の分割した投薬

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010173175A Pending JP2010275314A (ja) 2002-10-03 2010-07-30 神経学的障害を処置するための抗うつ剤の投薬量の段階的な漸増ならびに毎日の分割した投薬

Country Status (7)

Country Link
US (1) US20040106681A1 (enExample)
EP (1) EP1558231A4 (enExample)
JP (2) JP2006504795A (enExample)
AU (1) AU2003284005B2 (enExample)
CA (1) CA2500662A1 (enExample)
MX (1) MXPA05003550A (enExample)
WO (1) WO2004030633A2 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US7704527B2 (en) * 2002-10-25 2010-04-27 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
PT1601349E (pt) 2003-02-14 2008-10-27 Pf Medicament Utilização do enantiómero (1s, 2r) do milnaciprano para a preparação de um medicamento
FR2851163B1 (fr) 2003-02-14 2007-04-27 Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament
AU2004312530A1 (en) * 2003-12-29 2005-07-21 Sepracor Inc. Pyrrole and pyrazole DAAO inhibitors
US20060002999A1 (en) 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
EP1845968A2 (en) 2004-11-24 2007-10-24 Neuromolecular Pharmaceuticals, Inc Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease
WO2007006003A2 (en) 2005-07-06 2007-01-11 Sepracor Inc. Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
AU2012203789B2 (en) * 2005-09-28 2014-12-11 Forest Laboratories Holdings Limited Milnacipran for the long-term treatment of fibromyalgia syndrome
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
JP5438975B2 (ja) * 2006-01-06 2014-03-12 サノビオン ファーマシューティカルズ インク テトラロン系モノアミン再取り込み阻害剤
KR101294014B1 (ko) 2006-01-06 2013-08-09 선오비온 파마슈티컬스 인코포레이티드 모노아민 재흡수 저해제로서의 시클로알킬아민
DK2656842T3 (en) * 2006-03-27 2016-11-07 Univ California Androgen receptor MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND androgen receptor-ASSOCIATED DISEASES
CA2648121C (en) 2006-03-31 2013-08-06 Sepracor Inc. Preparation of chiral amides and amines
US20090280171A1 (en) * 2006-04-13 2009-11-12 Accu-Break Technologies, Inc. Method of treatment with predictably breakable pharmaceutical tablets
US7884124B2 (en) * 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
US7579370B2 (en) * 2006-06-30 2009-08-25 Sepracor Inc. Fused heterocycles
US20080058318A1 (en) * 2006-08-09 2008-03-06 Cypress Bioscience, Inc. Milnacipran for the treatment of cognitive dysfunction associated with fibromyalgia
US20080058317A1 (en) * 2006-08-09 2008-03-06 Cypress Bioscience, Inc. Milnacipran for the treatment of fatigue associated with fibromyalgia syndrome
US20080082066A1 (en) * 2006-10-02 2008-04-03 Weyerhaeuser Co. Crosslinked carboxyalkyl cellulose fibers having non-permanent and temporary crosslinks
US7902252B2 (en) * 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
MX2009007410A (es) * 2007-01-18 2009-09-09 Sepracor Inc Inhibidores de d-aminoacido oxidasa.
BRPI0811639A2 (pt) 2007-05-31 2014-09-30 Sepracor Inc Cicloaquilaminas fenil substituídas como inibidores da recaptação de monoamina
WO2010017418A1 (en) * 2008-08-07 2010-02-11 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
WO2011017634A2 (en) * 2009-08-07 2011-02-10 Sepracore Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
JP2013510176A (ja) 2009-11-06 2013-03-21 ピエール ファーブル メディカモン （１ｓ，２ｒ）−２−（アミノメチル）−ｎ，ｎ−ジエチル−１−フェニルシクロプロパンカルボキサミドの新規結晶形態
EP3132793A1 (en) 2009-12-02 2017-02-22 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
CA2818491A1 (en) * 2010-11-18 2012-05-24 White Mountain Pharma, Inc. Methods for treating chronic or unresolvable pain and/or increasing the pain threshold in a subject and pharmaceutical compositions for use therein
FR2978350B1 (fr) 2011-07-28 2013-11-08 Pf Medicament Medicament a base de levomilnacipran pour la rehabilitation fonctionnelle apres accident neurologique aigu
IL312316A (en) 2012-09-26 2024-06-01 Aragon Pharmaceuticals Inc Antiandrogens for the treatment of castration-resistant prostate cancer without metastases
WO2014204933A1 (en) 2013-06-17 2014-12-24 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
MX373227B (es) * 2014-05-09 2020-04-21 Tecnimede Sociedade Tecnico Medicinal S Sales farmacéuticamente aceptables de enantiómeros de pirlindol para utilizarse en medicina.
US9814712B2 (en) * 2014-05-09 2017-11-14 Tecnimede Sociedade Tecnico-Medicinal S.A. (S)-pirlindole and its pharmaceutically acceptable salts for use in medicine
RS56590B1 (sr) * 2014-05-09 2018-02-28 Tecnimede Sociedade Tecnico Medicinal S A (r)-pirlindol i njegove farmaceutski prihvatljive soli za upotrebu u medicini
CA3064006C (en) * 2017-05-19 2025-09-16 Biscayne Neurotherapeutics Inc Modified release pharmaceutical compositions of huperzine and methods of using the same
JOP20200076A1 (ar) 2017-10-16 2020-04-30 Aragon Pharmaceuticals Inc مضادات أندروجين لعلاج سرطان البروستاتا غير النقيلي المقاوم للاستئصال
CN115135317A (zh) 2020-01-22 2022-09-30 西洛斯治疗有限公司 减少nmda拮抗剂的副作用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352683A (en) * 1993-03-05 1994-10-04 Virginia Commonwealth University Medical College Of Virginia Method for the treatment of chronic pain
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
EP0906104A4 (en) * 1996-03-25 2003-12-10 Lilly Co Eli PAIN TREATMENT PROCESS
WO1997035586A1 (en) * 1996-03-25 1997-10-02 Eli Lilly And Company Method for treating pain
US5912256A (en) * 1996-06-20 1999-06-15 Eli Lilly And Company Compounds having effects on serotonin-related systems
GB9617990D0 (en) * 1996-08-29 1996-10-09 Scotia Holdings Plc Treatment of pain
US6284794B1 (en) * 1996-11-05 2001-09-04 Head Explorer Aps Method for treating tension-type headache with inhibitors of nitric oxide and nitric oxide synthase
US6552055B2 (en) * 1996-12-11 2003-04-22 Dana-Farber Cancer Institute Methods and pharmaceutical compositions for inhibiting tumor cell growth
WO1998050044A1 (en) * 1997-05-07 1998-11-12 Algos Pharmaceutical Corporation Composition and method combining an antidepressant with an nmda receptor antagonist, for treating neuropathic pain
US5994363A (en) * 1998-08-24 1999-11-30 Pentech Pharmaceuticals, Inc. Amelioration of apomorphine adverse effects
US6489341B1 (en) * 1999-06-02 2002-12-03 Sepracor Inc. Methods for the treatment of neuroleptic and related disorders using sertindole derivatives
PL196996B1 (pl) * 1999-07-01 2008-02-29 Upjohn Co Zastosowanie optycznie czystej (S,S)-reboksetyny lub jej dopuszczalnej farmaceutycznie soli do wytwarzania leku
CA2383522C (en) * 1999-08-16 2011-12-06 Revaax Pharmaceuticals, Llc Neurotherapeutic composition and method
GB2355191A (en) * 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
CN1396829A (zh) * 2000-02-24 2003-02-12 法玛西雅厄普约翰美国公司 新的药物联合形式
MXPA03006003A (es) * 2001-01-02 2005-09-08 Upjohn Co Nuevas combinaciones de farmacos.
US20020147196A1 (en) * 2001-04-05 2002-10-10 Quessy Steven Noel Composition and method for treating neuropathic pain
US6638981B2 (en) * 2001-08-17 2003-10-28 Epicept Corporation Topical compositions and methods for treating pain
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US20040034101A1 (en) * 2001-11-05 2004-02-19 Cypress Bioscience, Inc. Treatment and prevention of depression secondary to pain (DSP)
US6635675B2 (en) * 2001-11-05 2003-10-21 Cypress Bioscience, Inc. Method of treating chronic fatigue syndrome
CA2475763A1 (en) * 2002-02-12 2003-08-21 Cypress Bioscience, Inc. Methods of treating attention deficit/hyperactivity disorder (adhd)
WO2003077897A1 (en) * 2002-03-15 2003-09-25 Cypress Bioscience, Inc. Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes
MXPA04011529A (es) * 2002-04-24 2005-08-15 Cypress Bioscience Inc Prevencion y tratamiento de trastornos somaticos funcionales, incluyendo trastornos relacionados con la tension.
JP2006506461A (ja) * 2002-10-25 2006-02-23 コルジウム ファーマシューティカル， インコーポレイテッド ミルナシプランのパルス型放出組成物
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
US20060024366A1 (en) * 2002-10-25 2006-02-02 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
WO2004105690A2 (en) * 2003-05-23 2004-12-09 Cypress Bioscience, Inc. Treatment of chronic pain associated with drug or radiation therapy
US20060039867A1 (en) * 2004-08-20 2006-02-23 Cypress Bioscience, Inc. Method for treating sleep-related breathing disorders with setiptiline
US20070021352A1 (en) * 2005-07-20 2007-01-25 Cypress Bioscience, Inc. Prevention and treatment of hearing disorders
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome

Similar Documents

Publication Publication Date Title
JP2006504795A5 (enExample)
RU2356547C2 (ru) Способы лечения рака с использованием ингибиторов hdac
JP2009525343A5 (enExample)
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
RU2010147287A (ru) Комбинированная композиция
HRP20130057T1 (hr) Lijeäśenje progresivne neurodegenerativne bolesti ibudilastom
JP2009543885A5 (enExample)
RU2010133489A (ru) Применение ингибиторов гамма-секретазы для лечения рака
JP2012515184A5 (enExample)
JP2013231087A5 (enExample)
JP2012193216A5 (enExample)
HRP20130544T4 (hr) Dugoročno liječenje hiv-infekcije sa tcm278
IL196425A0 (en) Pharmaceutical compositions containing ibuprofen and famotidine
RU2006101225A (ru) Пероральные лекарственные формы мемантина
AR045289A1 (es) Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento
RU2007103306A (ru) Композиции на основе ризедроната и способы их применения
RU2010109359A (ru) Азитромицин для лечения кожных заболеваний
JP2007238598A5 (enExample)
JP2009504774A5 (enExample)
JP2005068010A5 (enExample)
RU2008119454A (ru) Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом
Pergolizzi et al. Current and emerging COX inhibitors for treating postoperative pain following oral surgery
RU2002122084A (ru) Комбинация лекарственных препаратов, включающая миртазапин, для лечения депрессии и связанных растройств
RU2007119067A (ru) Средство для лечения синдрома раздраженного кишечника с преобладанием диареи
MA27723A1 (fr) Trousse utilisable a des fins pharmaceutiques